AU2010328555B2 - Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof - Google Patents

Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof Download PDF

Info

Publication number
AU2010328555B2
AU2010328555B2 AU2010328555A AU2010328555A AU2010328555B2 AU 2010328555 B2 AU2010328555 B2 AU 2010328555B2 AU 2010328555 A AU2010328555 A AU 2010328555A AU 2010328555 A AU2010328555 A AU 2010328555A AU 2010328555 B2 AU2010328555 B2 AU 2010328555B2
Authority
AU
Australia
Prior art keywords
composition
carboxylic acid
alkyl
prostanoid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010328555A
Other languages
English (en)
Other versions
AU2010328555A1 (en
Inventor
Robert M. Burk
Wha Bin Im
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010328555(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2010328555A1 publication Critical patent/AU2010328555A1/en
Application granted granted Critical
Publication of AU2010328555B2 publication Critical patent/AU2010328555B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010328555A 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof Ceased AU2010328555B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26789709P 2009-12-09 2009-12-09
US61/267,897 2009-12-09
PCT/US2010/055590 WO2011071620A1 (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Publications (2)

Publication Number Publication Date
AU2010328555A1 AU2010328555A1 (en) 2012-07-05
AU2010328555B2 true AU2010328555B2 (en) 2016-05-26

Family

ID=43503864

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010328555A Ceased AU2010328555B2 (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Country Status (16)

Country Link
US (2) US20110136872A1 (enExample)
EP (1) EP2509582A1 (enExample)
JP (2) JP5955774B2 (enExample)
KR (1) KR20120106788A (enExample)
CN (1) CN102762195B (enExample)
AR (1) AR078929A1 (enExample)
AU (1) AU2010328555B2 (enExample)
CA (1) CA2783707A1 (enExample)
CL (1) CL2012001545A1 (enExample)
IL (1) IL220240A0 (enExample)
MX (1) MX2012006622A (enExample)
NZ (1) NZ600577A (enExample)
RU (1) RU2012127869A (enExample)
SG (1) SG181600A1 (enExample)
TW (1) TW201138766A (enExample)
WO (1) WO2011071620A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6270848B2 (ja) 2012-08-27 2018-01-31 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
KR101535825B1 (ko) 2012-09-25 2015-07-10 엘지디스플레이 주식회사 표시장치 및 이의 라인결함 검출방법
WO2015175075A1 (en) * 2014-02-20 2015-11-19 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
ES2757798T3 (es) 2014-10-02 2020-04-30 Allergan Inc Profármacos de éster de gamma-lactamas y su uso

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US20070265330A1 (en) * 2005-03-10 2007-11-15 Old David W Substituted gamma lactams as therapeutic agents
US20090270392A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2123278A1 (en) * 2007-02-07 2009-11-25 Teika Pharmaceutical Co., Ltd. Eye drop reparation comprising latanoprost

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
WO2000004898A1 (en) * 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
ES2320770T3 (es) * 2004-05-26 2009-05-28 Arturo Jimenez Bayardo Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida.
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US20070265330A1 (en) * 2005-03-10 2007-11-15 Old David W Substituted gamma lactams as therapeutic agents
EP2123278A1 (en) * 2007-02-07 2009-11-25 Teika Pharmaceutical Co., Ltd. Eye drop reparation comprising latanoprost
US20090270392A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
JP5955774B2 (ja) 2016-07-20
AR078929A1 (es) 2011-12-14
CL2012001545A1 (es) 2012-08-31
IL220240A0 (en) 2012-07-31
KR20120106788A (ko) 2012-09-26
WO2011071620A1 (en) 2011-06-16
CN102762195B (zh) 2016-05-18
US20110136872A1 (en) 2011-06-09
MX2012006622A (es) 2012-08-15
NZ600577A (en) 2014-10-31
JP2013513606A (ja) 2013-04-22
SG181600A1 (en) 2012-07-30
TW201138766A (en) 2011-11-16
AU2010328555A1 (en) 2012-07-05
JP2016056207A (ja) 2016-04-21
RU2012127869A (ru) 2014-01-20
CN102762195A (zh) 2012-10-31
EP2509582A1 (en) 2012-10-17
CA2783707A1 (en) 2011-06-16
US20160220677A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
EP0789687B1 (en) Ep2-receptor agonists as agents for lowering intraocular pressure
AU739065B2 (en) Ep2-receptor agonists as neuroprotective agents for the eye
EP2526094B1 (en) Substituted chlorocyclopentanols for therapeutic applications
JP2020125355A (ja) 併用療法
US20150150880A1 (en) Hypotensive Lipid And Timolol Compositions And Methods Of Using Same
KR20100131976A (ko) 고 안압증의 치료를 위한 디플루오로바이페닐아미드 유도체
WO2009035565A1 (en) Prostaglandin analogues for implant devices and methods
US20160220677A1 (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
EP1808170B1 (en) Aqueous eye drops with accelerated intraocular migration
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
US7696235B2 (en) EP2 receptor agonists for treating glaucoma
US7662850B2 (en) Therapeutic substituted chlorocyclopentanols
US7960431B2 (en) Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension
US20100298436A1 (en) EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists
AU2006283208B2 (en) Sulfonamides
WO2007011720A2 (en) Cyclopentane n-lower alkyl heptenamide-5-cis-2- (3alapha- hydroxy-5-phenylpentyl) -3, ?5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
AU2013200669A1 (en) EP2 receptor agonists for treating glaucoma
CA2361906A1 (en) Water-soluble fluorinated sulfonamides as topical carbonic anhydrase inhibitors, for treating glaucoma
AU2014201651A1 (en) Hypotensive lipid and timolol compositions and methods of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired